| Literature DB >> 15137074 |
Inn H Y Yuk1, Matthew M Olsen, Scott Geyer, Sean P Forestell.
Abstract
This study demonstrates the novel use of the HeLaS3 human tumor cell line for propagating ONYX-411, a recombinant oncolytic adenoviral vector. HeLaS3 cells enabled high levels of vector production without the risk of generating vector recombinants, which is possible with HEK293 cells. The development of a high-cell-density perfusion process using ATF technology yielded production levels as high as 6 x 10(11) vp/mL, which was approximately sevenfold greater than the titers achieved in fed-batch bioreactors. Several experiments were performed at the bench (15 L) and pilot (70 L) scales to demonstrate the robust and scalable nature of this industrially relevant technology. Copyright 2004 Wiley Periodicals, Inc.Entities:
Mesh:
Year: 2004 PMID: 15137074 DOI: 10.1002/bit.20158
Source DB: PubMed Journal: Biotechnol Bioeng ISSN: 0006-3592 Impact factor: 4.530